BACKGROUND/OBJECTIVES: A significant proportion of Crohn's disease (CD) patients receiving infliximab (IFX) maintenance therapy show loss of responsiveness despite a good initial response. The factors other than immunomodulators that prevent IFX dose escalation have yet to be fully elucidated. This study was performed to identify clinical factors or concomitant therapies associated with sustained response to IFX. SUBJECTS/METHODS: Seventy-four consecutive CD patients who had successful IFX induction therapy between 2002 and 2010 underwent IFX maintenance therapy. Patients showing loss of response to IFX were treated with IFX intensification therapy. Factors involved in the sustained response to IFX were investigated retrospectively. RESULTS: After a median follow-up of 85 weeks, loss of response to IFX was observed in 30 (40.5%) cases. On logistic regression analysis, concomitant use of enteral nutrition (EN) therapy (elemental and/or polymeric formulas) was identified as an independent factor associated with sustained response to IFX. Receiver operating characteristic curve analysis indicated a cutoff value of 600 kcal/day. We divided the patients into the 'EN group' (X600 kcal/day) and 'control group' (o600 kcal/day). The cumulative number of loss of response was significantly lower in the EN group (odds ratio: 0.23, P ¼ 0.0043). Kaplan-Meier analysis confirmed the significantly lower rate of loss of response in the EN group (P ¼ 0.013). Multivariate hazard ratio was 0.37 (P ¼ 0.025). Type of EN formula did not affect the results. CONCLUSIONS: Concomitant use of EN X600 kcal/day is likely to yield a sustained response to IFX in CD patients.
INTRODUCTION
Crohn's disease (CD) is a chronic relapsing inflammatory disorder of the gastrointestinal tract. Although the precise etiology of CD remains unclear, recent studies have identified an outline of the pathogenesis of CD-genetic and environment factors disturb homeostasis of the intraluminal intestinal milieu, including gut microbiota and intestinal barrier function, leading to unbalancing of the host immune system and a continuing inflammatory response in the gastrointestinal tract. CD may involve any part of the gastrointestinal tract, and is commonly associated with complications such as strictures, abscesses and fistulas. [1] [2] [3] Until a decade ago, patients with CD were usually treated with conventional therapy, such as 5-aminosalicylates, corticosteroids, thiopurines and enteral nutrition (EN) with treatment goals consisting of immediate symptomatic control. Introduction of antitumor necrosis factor alpha (anti-TNF-a) therapies has markedly altered the paradigm of medical treatment aiming not only at reducing symptoms but also inducing mucosal healing and sustaining clinical remission of CD. 4 Infliximab (IFX) is an anti-TNF-a agent that was approved for use in CD in the USA in 1998 and in Europe in 1999. Several lines of evidence have demonstrated the superb efficacy of IFX for luminal CD and fistulizing CD. [5] [6] [7] [8] Even in patients with CD who show a good initial response to IFX, 25-40% show loss of response during maintenance therapy, and this occurs mostly within the first 6 months after commencement of treatment. [9] [10] [11] Although the precise mechanisms responsible for loss of response to IFX in CD are poorly understood, the immunogenicity of neutralizing antibodies to IFX that appear during scheduled treatment with IFX may have a role. In addition to neutralizing antibodies, low trough serum concentrations of IFX resulting from unexplored pharmacokinetic mechanisms have been implicated as risk factors for treatment failure.
Clinically, it is essential to manage loss of response to IFX. To prevent loss of response to IFX, concomitant use of immunomodulators has been shown to be associated with reduced IFX dose escalation. 12 There have been several studies of the mechanism by which concomitant immunomodulators may lead to improved efficacy. The first explanation is that immunomodulators may reduce the risk of formation of antibodies to IFX. Second, immunomodulators are additive to IFX in inducing apoptosis of lamina propria T lymphocytes and monocytes. The third mechanism may involve interactions between both sets of agents. 13 An increase in IFX dose to 10 mg/kg or reduction of the intervals of IFX infusion at 4 or 6 weeks represent effective strategies to rescue the response after loss of response. 7, 14, 15 On the other hand, switching to an alternative anti-TNF-a drug is an effective strategy and is currently considered one of the best options in patients intolerant to their primary anti-TNF-a therapy. From the viewpoint of health economics, it is preferable to establish a strategy for preventing loss of response to IFX. Factors other than immunomodulators that prevent IFX dose escalation have yet to be elucidated. Therefore, this study was performed to identify clinical factors or concomitant therapies associated with sustained response to IFX.
SUBJECTS AND METHODS Patients
In a retrospective cohort study, CD patients 16 years or older with successful induction of clinical remission by IFX induction therapy were consecutively recruited into this study during the period from October 2002 to June 2010 at a tertiary referral center in Japan (Department of Gastroenterology and Hepatology of Chiba University Hospital). Patients had been diagnosed with CD endoscopically, radiologically and histologically according to the report by the Research Committee of Inflammatory Bowel Disease set up by the Japanese Ministry of Health and Welfare. 16 
Study design
Recruited patients with CD had undergone IFX maintenance therapy at a dose of 5 mg/kg intravenously at intervals of 8 weeks for at least 6 months after successful induction therapy with IFX at 5 mg/kg intravenously at 0, 2 and 6 weeks. Before every infusion, physical examination was performed and CD activity index was recorded. Patients with a CD activity index score of X150 points and an increase in 470 points accompanied by positive serum C-reactive protein were defined as showing loss of response to IFX. All the patients who experienced loss of response to IFX were treated with IFX intensification therapy afterward (that is, reduced IFX infusion interval and/or increased IFX dose).
We examined the time to loss of response of IFX and then divided the patients into two groups: one group consisted of patients with sustained remission by IFX therapy and the other consisted of those with loss of response to IFX. We performed multivariate analysis with regard to gender distribution, age of disease onset, disease duration before starting IFX, age at starting IFX, area of involvement and concomitant use of EN therapy (elemental and/or polymeric formulas) between the two groups. Elental (Ajimomoto Pharmaceutical, Tokyo, Japan) was used as an elemental formula and Racol (Otsuka Pharmaceutical, Tokyo, Japan) as a polymeric formula. Daily dose of EN has been constant in each patient since starting IFX. Imuran (GlaxoSmithKline, Tokyo, Japan and UCB, Tokyo, Japan) and/or Leukerin (Ohara Pharmaceutical, Shiga, Japan) were used as azathioprine agents.
Statistical analysis
Quantitative values are expressed as means±s.d. Baseline characteristics were compared between the two groups using the Mann-Whitney U-test and Fisher's exact test. Logistic regression analysis was utilized to identify potential factors for sustained response. Receiver operating characteristic curve analysis was carried out to determine the appropriate cutoff quantity of factors affecting sustained response to IFX. Both Kaplan-Meier analysis and the Cox proportional hazards model were used to assess the longterm effects on sustained response to IFX. In Kaplan-Meier analysis, patients were censored if they had shown no loss of response to IFX at time of follow-up and the censored cases were counted by tick marks on survival curves when provided. All statistical analyses were performed using JMP statistical software version 9.0.2 (SAS Institute, Cary, NC, USA).
RESULTS

Demographic characteristics of the patients
Seventy-four consecutive patients were included in this cohort (75% males with an average age at IFX commencement of 31.2 years, range 18-60 years). Average age of disease onset was 23.7 years (range 13-53 years), and the disease duration before starting IFX was 91.4 months (range 9-290 months).
Analysis of causative factors in CD patients with loss of response to IFX After a median follow-up of 85 weeks (average: 101.7 weeks; range 25-402 weeks), loss of response to IFX was observed in 30 (49.5%) cases. The cumulative numbers of cases showing loss of response to IFX were 11, 21 and 26 cases in 1, 2 and 3 years after initiation if IFX, respectively. We then divided the patients into two groupsone group consisted of patients with sustained remission by IFX therapy, whereas the other consisted of those with loss of response to IFX. There were no differences in gender distribution, age of disease onset, disease duration before starting IFX, age at starting IFX or area of involvement between the two groups (Table 1) . Kaplan-Meier analyses also demonstrated no associations between gender distribution (Figure 1 ), disease duration before starting IFX (data not shown), age at starting IFX (data not shown) or area of involvement with loss of response to IFX (Figure 2) . However, as shown in Table 1 , quantity of concomitant EN taken daily by the patients with sustained remission was significantly higher (506.8 ± 77.6 kcal) than that by patients with loss of response to IFX (246.7 ± 69.9 kcal, P ¼ 0.0167). Multiple logistic regression analysis using factors including gender, age of disease onset, disease duration before starting IFX, age at starting IFX, area of involvement and concomitant EN also identified higher dose of EN therapy as an independent factor significantly associated with sustained response to IFX (odds ratio: 0.064, 95% confidence interval: 0.005-0.62, P ¼ 0.017).
Analysis of clinical background of patients taking ENX600 kcal/day To investigate the effects of EN on sustained remission with IFX, we next attempted to determine the cutoff volume of EN required for sustained remission. As shown in Figure 3 , receiver operating characteristic curve analysis indicated an EN dose of over 400 kcal/day was necessary for sustained remission with IFX. On the basis of this result, we divided the patients into the EN group (EN dose X600 kcal/day, n ¼ 29) and the control group (EN dose o600 kcal/day, n ¼ 45) after considering EN is usually prescribed by the 300 kcal unit in Japan. As shown in Table 2 , there were no significant differences in gender distribution, age of disease onset, disease duration before starting IFX, age at starting IFX, duration after starting IFX, area of involvement, smoking habit or concomitant medications between the two groups. Figure 4 . Finally, the multivariate hazard ratio adjusted by gender, disease duration before starting IFX, age at starting IFX and area of involvement was calculated by Cox proportional hazards model. The hazard ratio of occurrence of loss of response to IFX in EN group was 0.37 (95% confidence interval: 0.13-0.89, P ¼ 0.025). These results suggested that when patients with CD are treated with scheduled maintenance IFX treatment, concomitant EN treatment X600 kcal/day reduced the incidence rate of loss of response to IFX. We confirmed that type of EN formula (elemental and/or polymeric formulas) did not affect the results (data not shown).
DISCUSSION
This study showed that concomitant use of EN X600 kcal/day yields a sustained response to IFX maintenance therapy in patients with CD. Interestingly, neither concomitant use of immunomodulators nor smoking habit was associated with sustained response to IFX in this cohort study. EN was identified as a novel independent factor significantly associated with sustained response to IFX. Tanaka et al. 17 reported that patients who underwent episodic induction of IFX with concurrent EN showed a significantly higher response rate (68.4%) at week 16 than those without EN (32.4%, P ¼ 0.0026). They also demonstrated that usage of azathioprine and smoking status did not have any significant association with higher and prolonged response to IFX. In this study, the patients underwent scheduled maintenance therapy with IFX, whereas the previous study by Tanaka et al. 17 involved patients with episodic induction by IFX. Our 8-year cohort study has clearly showed that even in patients who underwent scheduled maintenance therapy, the ratio of the patients with loss of response to IFX decreased significantly with daily EN X600 kcal/day. In addition, similar to the previous study, 17 our data have shown that usage of azathioprine and smoking status did not have any significant association with loss of response to IFX. The results to this study suggested taking EN X600 kcal/day was an efficient and safe strategy to prevent loss of response to IFX.
EN has been shown to have beneficial effects for inducing and remaining remission in patients with CD. [18] [19] [20] Two different types of EN formula are prescribed for CD patients, that is, elemental formula and polymeric formula. Both were already shown to be equally efficient as primary therapies for active CD. 21 Differences in nitrogen sources of enteral feeds are not relevant to their therapeutic efficacy, as elemental diets and polymeric diets are equally effective. 22 The results of this study were consistent with previous reports indicating that EN is efficacious for maintaining clinical remission of patients with CD and elemental diets and polymeric diets were equally effective. We used EN not as primary Receiver operating characteristic (ROC) curve analysis. ROC curve analysis was carried out to determine the appropriate cutoff dose (kcal/day) of EN. This ROC curve is constructed by plotting sensitivity by (1-specificity) for each value of daily intake of EN. In the plot, a gray line drawn at a 451 angle tangent to the ROC curve indicates an optimal cutoff point.
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The mechanisms of EN underlying therapeutic response remain to be fully elucidated. Several theories have been proposed including reduced antigenic load, provision of trophic amino acids, alterations in gut flora and immune-modulating effects of fatty acids supplied by the feed. Several amino acids, which are the main components of the elemental formula, have recently been reported to alleviate gut inflammation in a colitis model. 23, 24 Histidine was demonstrated to inhibit nuclear factor-kB activation, following downregulation of proinflammatory cytokine production by macrophages in an interleukin-10-deficient cell transfer model. 25 With regard to the polymeric formula, immunemodulating effects of fatty acids are thought to have an important role in the maintaining effect of EN. 26 In addition to the mechanisms discussed above, we considered that the lower ratio of loss of response in patients taking X600 kcal/day EN was attributable to bowel rest resulting from drinking EN liquid formula. As the common feature of both formulae is that they are liquid in nature. CD patients can be exposed to several exacerbation factors, such as taking indigestible food and over-eating. The liquid nature of the diet may account for the improvement or remission of CD because of its ease of transportation through the narrowed small bowel in a patient with CD instead of provocation because of the presence of indigestible solid components. 27 Although the precise mechanisms responsible for loss of response to IFX in CD are not fully understood, the immunogenicity of neutralizing antibodies to IFX that appear during scheduled treatment with IFX may contribute to loss of response. In addition to neutralizing antibodies, low trough serum concentrations of IFX resulting from unexplored pharmacokinetic mechanisms have been implicated as risk factors for treatment failure. Although speculative, the mechanism may involve repetitive flare-up of CD or persistent TNF-mediated disease activity resulting in consumption of IFX. 10 Prevention of repetitive disease flare-up by taking EN daily is likely to reduce consumption of IFX, resulting in a decreased incidence of loss of response to this drug.
In general, patients hope to take less volume of EN as clinical remission is maintained. Therefore, it is important to determine the minimally required volume of EN for maintaining clinical remission from the viewpoint of adherence to EN by patients with CD. Our study demonstrated that the ratio of patients with loss of response decreases significantly with daily EN intake of X600 kcal/day. Previous studies have indicated minimally required volumes of EN for maintaining clinical remission in patients with CD. Maintenance of remission was reported to be successful in 95% of patients taking 430 kcal/kg ideal body weight/day of EN. 28, 29 A randomized controlled trial demonstrated the effectiveness of daily 900-1200 kcal of elemental diet (half elemental diet) compared with a free diet group taking all nutrients via their usual unrestricted meals. The relapse rate in the half elemental diet group was significantly lower (34.6% vs 64.0%; multivariate hazard ratio 0.40 (95% confidence interval: 0.16-0.98)) than that in the free diet group. 30 As described above, 900-1500 kcal of EN is necessary to sustain remission in patients with CD. In this study, the cutoff value was 600 kcal, which was lower than that when concomitant IFX was not used. Our results suggested that scheduled maintenance IFX treatment is able to reduce the volume of EN that is needed to maintain remission of CD to 600 kcal/day.
There are several limitations to our study. It is a retrospective study without randomization, blinding or sample size calculations. Our primary objective in this retrospective cohort study was to identify clinical factors or concomitant therapies associated with sustained response to IFX in patients with CD. Randomized controlled trials should be carried out to confirm the efficacy of EN on sustained response to IFX in patients with CD. Furthermore, the effects of concomitant EN on the levels of antibody to IFX and trough levels of IFX should be determined. In this study, a certain and constant amount of EN was started before IFX treatment or at the beginning of IFX treatment. Thus, it would be of value to further evaluate whether EN was effective in patients that have already lost response to IFX.
In conclusion, this is the first report indicating that concomitant use of EN therapy prevents loss of response to IFX in patients with CD. This 8-year cohort study demonstrates concomitant use of EN at a dose of X600 kcal/day yields a sustained response to IFX maintenance therapy in patients with CD. The results of this study indicated that along with concomitant immunomodulators and smoking cessation, loss of response to IFX in CD patients appears to be delayed by use of EN X600 kcal/day. Moreover, the economic merit of concomitant EN is superior to intensification of IFX. Concomitant EN should be reconsidered in the clinical management of patients with CD treated with anti-TNF-a regimens.
